Telix Pharmaceuticals is trading at A$13.64, up 4.92%, with biotech-sector strength a possible explanation for the November 3 move. - Telix’s listed announcements that day concerned director interests and securities administration; they provided no price-causation commentary. - A Capital Markets Day is scheduled for November 4, but available evidence does not establish that it drove the move.